Today: 1 July 2026
Browse Category

Pharmaceutical Industry 26 September 2025 - 13 November 2025

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics shares jumped today after the U.S. FDA accepted the company’s resubmitted Biologics License Application for ONS‑5010/LYTENAVA, its bevacizumab-based eye drug for wet AMD, and set a PDUFA review date of December 31, 2025. Here’s what investors need to know. This morning, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted the company’s resubmitted Biologics License Application for ONS‑5010/LYTENAVA, its investigational ophthalmic formulation of bevacizumab for the treatment of wet age‑related macular degeneration. GlobeNewswire+2Outlook Therapeutics+2
13 November 2025
··
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire Below is a complete roundup of today’s major developments around Mersana Therapeutics — structured and optimized for readers who find this via Google News or Discover.
13 November 2025
···
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin therapies for myeloproliferative neoplasms and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Damora’s approach is aimed squarely at mutant calreticulin—a well‑validated genetic driver in segments of essential thrombocythemia and myelofibrosis. Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond today’s largely symptom‑managing therapies. Early clinical work from other groups has already shown that mutCALR‑specific antibodies can inhibit oncogenic signaling without harming normal hematopoiesis, underscoring the potential for the class. PMC
10 November 2025
··
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a few points shy of its 52-week peak of $43.72investing.com. Even before this week’s jump, Rigel had been a big winner in 2025. Year-to-date the stock had already gained roughly 82% through early Novembernasdaq.com, massively outperforming the S&P 500nasdaq.com. Rigel was recently highlighted by CNBC as one of the top-performing Bay Area biotech stocks, with shares up ~50% over the past three months alonestocktradersmarket.com. The rally has been fueled by the company’s rapid revenue growth and newfound profitability. “We have a business that’s growing substantially,” CEO Raul Rodriguez noted in a recent CNBC interviewstocktradersmarket.com. He pointed out that Rigel’s revenues grew ~30% annually on average over the
5 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings. From a chart perspective, Pfizer has clear support around the low-$20s – investors stepped in at ~$21 during 2025’s sell-offs, likely viewing the dividend yield as too attractive at those levels. On the upside, $28–$30 is a resistance zone, as rallies in 2024 and 2025 fizzled out there amid broader market weakness and company-specific news. A decisive break above $28 could signal a bullish trend change, but that may require tangible
4 November 2025
·····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com: Formally incorporated in 2022, Kenvue began trading on the NYSE in May 2023 after a highly anticipated IPOen.wikipedia.org. The IPO raised $3.8 billion – the largest U.S. listing in nearly two years – and initially valued Kenvue around $41 billionen.wikipedia.org. Johnson & Johnson retained a ~90% stake initially, but by July 2023 J&J had fully divested via a share exchange, making Kenvue a fully independent companyen.wikipedia.org. The new company immediately landed in the S&P 500 and even the S&P 500 Dividend Aristocrats indexen.wikipedia.org.
4 November 2025
···
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock. Recent 2025 highlights: The first half of 2025 saw Zoetis deliver solid growth. In Q1, revenue grew just 1% on a reported basis but a robust 9% on an organic basis once currency and divestitures were stripped outnews.zoetis.com. CEO Kristin Peck praised “our diversified portfolio across markets and species” and the strong demand for innovative pet products driving those resultsnews.zoetis.com. By Q2, reported growth improved to +4% and Zoetis raised its full-year outlook at the timemyvetcandy.commyvetcandy.com. Key growth drivers included blockbuster pet parasiticides, dermatology meds, and new monoclonal antibody pain therapies Librela® and Solensia®myvetcandy.commyvetcandy.com.
4 November 2025
··
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day priorstockinvest.us. That single-day gain of +30.8% crowned CURR as one of the market’s top percentage gainers. In fact, the stock has rallied five days in a row, more than doubling amid surging volumestockinvest.us. This momentum continued into Nov 3, with an opening trade around $3.52 and only a modest pullback from last week’s peak. By comparison, the share price was mere pennies over the summer, reflecting a 1-for-### reverse split that helped propel the nominal price into dollars. Investors who held through the restructuring have seen a dramatic rebound in value in recent weeks. Such volatility cuts both ways. Intraday swings have been extreme – on Oct 31 the stock fluctuated nearly 27% from low to highstockinvest.us. Technical analysts note that CURR/AVRW is “very high risk” in the near term due to this volatilitystockinvest.us. Notably, its 14-day RSI spiked above 85, an overbought level that often precedes a cooldownstockinvest.us. In short, the stock’s price action has been breathtaking, but traders should brace for turbulence. Even
3 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39ts2.techstockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21stockanalysis.com, versus an average of only ~14 million in prior monthstipranks.com. In recent days, RANI dipped as low as ~$1.42 but rebounded sharply on Oct 31. Year-to-date the stock is still well off its 2021 highs, but the October news has put it in breakout mode. Several catalysts drove the recent moves. On Oct 17, 2025, Rani announced a landmark licensing agreement with Chugai Pharmaceutical: an up to $1.09 billion deal for an oral biologic programreuters.comts2.tech. At the same time Rani disclosed a heavily oversubscribed $60.3M private placement at $0.48/share led by Samsara BioCapitalir.ranitherapeutics.comts2.tech. Together these moves greatly extend Rani’s runway.
31 October 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 Marketbeat. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector Nasdaq. By comparison, an index of large pharmaceutical stocks was up modestly, making BMY one of 2025’s laggards. However, the tone shifted after the October 30 earnings release. BMY rallied about 3–4% in immediate reaction, climbing into the mid-$44s Reuters. This bounce, while modest, is notable given the stock’s recent slump and indicates some relief from investors that results and guidance were better than feared. Even after the pop, BMY remains near multi-year lows and trades at inexpensive valuations. The company’s dividend yield now stands around 5.6%, among the highest in big pharma ts2.tech. Such a yield suggests the market has driven the stock price down to a level where income-focused investors are being handsomely compensated to wait for a turnaround.
30 October 2025
··
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous closestockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303reuters.com. Over the past year, CI shares have traded between roughly $257 and $350stockanalysis.com, reflecting volatility in the insurance sector. Despite the pullback, Cigna’s valuation metrics remain attractive: at ~16x forward earnings, it still trades well below historical levels. Analysts note that a year-long surge left CI ripe for profit-taking. As Morningstar’s Julie Utterback observed, Cigna “maintained the status quo from a 2025 guidance perspective, which is probably what is keeping shares flat”reuters.com. In other words, the company stuck to its outlook, so the stock is trading largely on fundamentals rather than any new surprises.
30 October 2025
···
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety threshold for a mandatory pause. Intellia’s response was swift: dosing of new and existing patients was suspended in both the MAGNITUDE trial and a parallel MAGNITUDE-2 trial for ATTR with polyneuropathy, and regulators were notified ca.investing.com. “In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment … as we investigate this recent event,” said Intellia President and CEO John Leonard, M.D., adding that the company is “engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.” ca.investing.com. The affected patient has been hospitalized and is receiving medical care,
27 October 2025
···
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst was the Novartis takeover rumor that broke on August 6, 2025: A Financial Times report revealed Novartis was eyeing Avidity, sending RNA stock up 23% to ~$47 in a single day reuters.com. That spike marked a turning point – investors began pricing in a potential acquisition premium. In the weeks after, Avidity’s stock oscillated in the upper-$40s as markets awaited either confirmation of a deal or further trial data. By the week of Oct. 23, shares were holding around $49 with relatively low volatility, reflecting the market’s “wait-and-see” stance.
27 October 2025
·····
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is “Buy” based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs, the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news and analyses fiercepharma.com fiercepharma.com investing.com ts2.tech gilead.com; Reuters and Fierce Pharma reports reuters.com fiercepharma.com; analyst reports and MarketNews investing.com investing.com. Each cited source provides details on the topics above.
18 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI shares jumped over +150%, and the rally continued after the opening bellts2.techts2.tech. The stock — which had closed at just $0.47 the day before — briefly hit about $1.37 intraday on extremely heavy volumets2.techts2.tech. By midday, RANI was still trading around $1.30, up ~180% on the day, marking a stunning one-day surge that lifted the stock out of penny-stock territoryts2.tech. Such an explosive move was accompanied by a frenzy of trading. Approximately 70 million RANI shares changed hands on Oct. 17 – a staggering spike compared to the stock’s meager 3-month average of around 318,000 shares per dayts2.tech. This suggests intense speculative interest, as traders piled into the stock on the breaking news. Notably, even after soaring nearly 200%, RANI’s price was still down roughly 65% year-to-date and over 80% below its level one year agots2.tech, underscoring how beaten-down the stock had been before this turnaround. By closing at $1.64, Rani also regained compliance with Nasdaq’s $1.00 minimum bid requirement, easing imminent delisting worriests2.tech.
18 October 2025
···
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com. This dramatic sell-off came despite broader markets being relatively calm – the S&P 500 fell only ~0.6% on Thursday nasdaq.com. In other words, Kenvue’s slump is largely company-specific, not a general market downturn. As of now, year-to-date performance is deeply in the red, a stark contrast to the flat or modest gains for major indices. The stock had already been trending down for weeks before this latest drop, reflecting growing unease around Kenvue’s unique challenges.
17 October 2025
···
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonistreuters.com. On October 10, 2025, The Wall Street Journal broke the story that J&J is negotiating a purchase of Protagonist Therapeuticsreuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra since a 2017 collaboration dealreuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early confidence in the programreuters.com. According to Reuters, the discussions are driven by J&J’s strategic need to bolster its drug pipeline, especially in immunologyreuters.com. J&J’s top-selling autoimmune drug Stelara is now facing cheap biosimilar competition, so the company is keen to fill that revenue gapreuters.com. Protagonist’s Icotrokinra could fit the bill: Leerink Partners analysts project this oral IL-23 receptor antagonist could achieve $9.5 billion in peak annual sales globallyreuters.com. They describe it as potentially “one of the most impactful immunology drug launches of this decade”reuters.com. Acquiring Protagonist would allow J&J to fully own Icotrokinra’s future, rather than pay royalties – a strong incentive given the drug’s promise.
10 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

In early September 2025, Pfizer was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive news on the pipeline. Over the past month, PFE is up about 10%. The 52-week range is approximately $20.9–$30.4 companiesmarketcap.com, so the stock is near the top of that range after the recent jump. Trading volumes were unusually high on Sept 30 and Oct 1 investing.com, underscoring heavy investor interest. Key catalyst days: Sept 30 and Oct 1 correspond to the Trump price-cut announcement and its follow-up investing.com reuters.com.
2 October 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 and lagging the broader healthcare sector. Over the past 12 months, the stock is down roughly 18%. The 52-week high was $30.43, and shares now sit not far above their year’s low of $20.92 stockanalysis.com. By market capitalization, Pfizer remains one of the world’s largest pharmaceutical companies, but its valuation has compressed significantly from pandemic-era peaks. This underperformance stems largely from the post-pandemic “hangover.” Pfizer’s once record-breaking COVID-19 product sales have dropped sharply, creating a tough comparison and denting investor sentiment. In 2022, Pfizer’s COVID vaccine and antiviral pill brought in a combined $37.8 billion in revenue; by 2024 that fell to $12.5 billion. Wall Street expects Pfizer’s total earnings per share to have more than halved from $6.58 in 2022 to about $3.05 in 2025. This “COVID cliff” and concerns over upcoming patent expirations have weighed heavily on the stock’s performance.
26 September 2025
···
1 … 7 8 9

Stock Market Today

  • Pacific Current Group Tells ASX About Progress on Buy-Back Plan
    June 30, 2026, 11:38 PM EDT. Pacific Current Group Ltd (ASX: PAC) gave an update to the Australian Securities Exchange (ASX) on its on-market share buy-back program. The company is buying back its shares on market. Pacific Current is aiming to boost shareholder value through capital management. The announcement may affect stock liquidity and price. Investors can watch ASX announcements for more detail on the buy-back.
Go toTop